Type 2 diabetes | Type 1 diabetes | |||||||||||||||
Cohort 1 | Cohort 2 | Cohort 1 | Cohort 2 | |||||||||||||
Normo | Micro | Macro | Total | Normo | Micro | Macro | Total | Normo | Micro | Macro | Total | Normo | Micro | Macro | Total | |
GFR ≥90 | 15.4 | 6.5 | 1.2 | 23.1 | 17.8 | 3.9 | 0.4 | 22.1 | 27.0 | 4.9 | 0.4 | 32.3 | 39.6 | 3.0 | 0.3 | 42.9* |
GFR 60–89 | 45.1 | 13.7 | 3.3 | 62.1 | 52.1 | 10.3 | 2.0 | 64.4 | 50.2 | 7.0 | 3.5 | 60.7 | 44.9 | 5.6 | 0.0 | 50.5 |
GFR <60 | 6.9 | 3.9 | 4.0 | 14.8 | 7.9 | 3.2 | 2.5 | 13.6 | 2.8 | 1.4 | 2.8 | 7.0 | 3.3 | 0.7 | 2.6 | 6.6 |
Total | 67.4 | 24.1 | 8.5 | 100.0 | 77.8† | 17.4 | 4.9 | 100.0 | 80.0 | 13.3 | 6.7 | 100.0 | 87.8‡ | 9.2 | 3.0 | 100.0 |
Percentages are given.
*p<0.001,
†p<0.05 by χ2 test (3×2) to analyze the distribution of albuminuria categories (three groups) between cohort 1 and cohort 2 in type 2 and type 1 diabetes, respectively.
c p<0.05 by χ2 test (3×2) to analyze the distribution of GFR categories (three groups) between cohort 1 and cohort 2 in type 1 diabetes.
GFR, glomerular filtration rate; KDIGO, Kidney Disease Improving Global Outcomes.